Watson Gets FTC Nod For $5.5B Actavis Buy, With Concessions
By Scott Flaherty ( October 16, 2012, 12:53 PM EDT) -- The Federal Trade Commission on Monday cleared Watson Pharmaceuticals Inc.'s proposed €4.25 billion ($5.5 billion) purchase of Actavis Inc. after the generics maker agreed to divest 18 of its drugs to competitors to allay antitrust concerns....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.